Skip to main content

Envisioning is an emerging technology research institute and advisory.

LinkedInInstagramGitHub

2011 — 2026

research
  • Reports
  • Newsletter
  • Methodology
  • Origins
  • Vocab
services
  • Research Sessions
  • Signals Workspace
  • Bespoke Projects
  • Use Cases
  • Signal Scanfree
  • Readinessfree
impact
  • ANBIMAFuture of Brazilian Capital Markets
  • IEEECharting the Energy Transition
  • Horizon 2045Future of Human and Planetary Security
  • WKOTechnology Scanning for Austria
audiences
  • Innovation
  • Strategy
  • Consultants
  • Foresight
  • Associations
  • Governments
resources
  • Pricing
  • Partners
  • How We Work
  • Data Visualization
  • Multi-Model Method
  • FAQ
  • Security & Privacy
about
  • Manifesto
  • Community
  • Events
  • Support
  • Contact
  • Login
ResearchServicesPricingPartnersAbout
ResearchServicesPricingPartnersAbout
  1. Home
  2. Research
  3. Helix
  4. Digital Twin Physiology Platforms

Digital Twin Physiology Platforms

Patient-specific simulation stacks predicting therapy response.
Back to HelixView interactive version

Digital twin physiology platforms create patient-specific computational models that merge data from genomics, laboratory tests, wearable devices, and medical imaging to simulate how individual patients will respond to different interventions before treatment is administered. These cloud-based systems allow clinicians to test different therapeutic approaches virtually, modeling the effects of senolytics, metabolic drugs, gene therapies, or other interventions on a patient's specific physiology, reducing trial-and-error care and enabling more personalized, effective treatments. Longevity programs are using these platforms to optimize interventions for individual patients.

This innovation addresses the challenge of personalized medicine, where predicting how individual patients will respond to treatments is difficult, leading to trial-and-error approaches that can waste time and resources while patients suffer. By creating accurate digital models of individual patients, these platforms enable clinicians to predict treatment outcomes and optimize interventions before administering them. Companies and research institutions are developing these platforms for various applications including longevity medicine, oncology, and chronic disease management.

The technology is particularly valuable for complex conditions where individual responses vary significantly, enabling truly personalized medicine. As the technology improves and integrates more data sources, it could become a standard tool for treatment planning. However, ensuring model accuracy, integrating diverse data sources, and validating predictions remain challenges. The technology represents an important evolution toward personalized medicine, but requires continued development to achieve the accuracy and reliability needed for clinical use. Success could transform healthcare by enabling truly personalized treatment planning, but the path to clinical adoption requires careful validation and integration with clinical workflows.

TRL
5/9Validated
Impact
5/5
Investment
4/5
Category
Software

Related Organizations

Dassault Systèmes logo
Dassault Systèmes

France · Company

95%

Software corporation specializing in 3D design and digital mock-ups.

Developer
Unlearn.AI logo
Unlearn.AI

United States · Startup

95%

Creates 'Prognostic Digital Twins' of patients to populate control arms in clinical trials, reducing the need for placebo patients.

Developer
HeartFlow logo
HeartFlow

United States · Company

90%

Uses CT scan data to create a digital model of coronary arteries and simulate blood flow (FFRct) to diagnose heart disease.

Developer
SimBioSys

United States · Startup

90%

Develops TumorScope, a platform that creates 3D digital twins of tumors to simulate response to surgical and drug interventions.

Developer
Twin Health

United States · Startup

90%

Offers the 'Whole Body Digital Twin' service, using sensor data and AI to reverse chronic metabolic diseases like diabetes.

Developer
FEops

Belgium · Company

85%

Provides 'HEARTguide', a predictive simulation platform for structural heart interventions based on patient-specific digital twins.

Developer
Novadiscovery logo
Novadiscovery

France · Company

85%

Provides an in silico clinical trial platform (JINKO) that models disease pathophysiology and drug effects.

Developer
Virtonomy logo
Virtonomy

Germany · Startup

85%

Creates digital twins of patient anatomies to test medical devices virtually (v-Patients) before clinical trials.

Developer
PrediSurge

France · Startup

80%

Develops digital twin software for endovascular interventions, simulating stent-graft deployment in patient-specific aortas.

Developer
Quris-AI

Israel · Startup

75%

Uses a 'Bio-AI' platform that combines organ-on-chip data with machine learning to predict drug safety in humans.

Developer

Supporting Evidence

Evidence data is not available for this technology yet.

Connections

Software
Software
Digital Avatars of Human Physiology

Multiscale simulations forecasting intervention impacts.

TRL
4/9
Impact
4/5
Investment
4/5
Hardware
Hardware
Organ-on-Chip & Multi-Organ Microphysiological Systems

Microfluidic platforms simulating aging and rejuvenation pathways.

TRL
6/9
Impact
4/5
Investment
3/5
Applications
Applications
Precision Longevity Interventions

Personalized stacks of therapeutics and lifestyle modifications.

TRL
7/9
Impact
4/5
Investment
4/5
Software
Software
In-Silico Longevity Drug Repurposing Engines

AI platforms identifying geroprotective properties in existing non-longevity drugs.

TRL
8/9
Impact
4/5
Investment
3/5
Software
Software
Microbiome Analytics Platforms

Metagenomic analytics delivering strain-level insights for therapeutics.

TRL
6/9
Impact
4/5
Investment
4/5
Software
Software
Adverse Event Prediction Systems

ML models flagging toxicity and safety issues during clinical trials.

TRL
6/9
Impact
5/5
Investment
4/5

Book a research session

Bring this signal into a focused decision sprint with analyst-led framing and synthesis.
Research Sessions